AU Patent

AU2015210331A1 — Pharmaceutical dosage form for immediate release of an indolinone derivative

Assigned to Boehringer Ingelheim International GmbH · Expires 2015-08-27 · 11y expired

What this patent protects

PHARMACEUTICAL DOSAGE FORM FOR IMMEDIATE RELEASE OF AN INDOLINONE DERIVATIVE Abstract The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl piperazin- 1 -yl)-methylcarbonyl)-N-…

USPTO Abstract

PHARMACEUTICAL DOSAGE FORM FOR IMMEDIATE RELEASE OF AN INDOLINONE DERIVATIVE Abstract The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl piperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 -phenyl-methylene] -6 methoxycarbonyl-2-indolinone-monoethanesulphonate.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015210331A1
Jurisdiction
AU
Classification
—
Expires
2015-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.